Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.1% Following Analyst Downgrade
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s stock price traded down 6.1% on Tuesday after Guggenheim lowered their price target on the stock from $55.00 to $45.00. Guggenheim currently has a buy rating on the stock. Intellia Therapeutics traded as low as $8.00 and last traded at $8.03. 1,721,555 shares changed hands during mid-day […]
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s stock price traded down 6.1% on Tuesday after Guggenheim lowered their price target on the stock from $55.00 to $45.00. Guggenheim currently has a buy rating on the stock. Intellia Therapeutics traded as low as $8.00 and last traded at $8.03. 1,721,555 shares changed hands during mid-day […]
